These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 12631619)
1. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619 [TBL] [Abstract][Full Text] [Related]
2. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Berenson JR; Ma HM; Vescio R Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563 [TBL] [Abstract][Full Text] [Related]
4. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322 [TBL] [Abstract][Full Text] [Related]
5. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813 [TBL] [Abstract][Full Text] [Related]
6. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913 [TBL] [Abstract][Full Text] [Related]
7. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062 [TBL] [Abstract][Full Text] [Related]
8. NF-kappa B as a therapeutic target in multiple myeloma. Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171 [TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Dai Y; Rahmani M; Grant S Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039 [TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Tan C; Waldmann TA Cancer Res; 2002 Feb; 62(4):1083-6. PubMed ID: 11861386 [TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091 [TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973 [TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition in cancer: development of PS-341. Adams J Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819 [TBL] [Abstract][Full Text] [Related]
16. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018 [TBL] [Abstract][Full Text] [Related]
17. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
18. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421 [TBL] [Abstract][Full Text] [Related]
19. The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Dong QG; Sclabas GM; Fujioka S; Schmidt C; Peng B; Wu T; Tsao MS; Evans DB; Abbruzzese JL; McDonnell TJ; Chiao PJ Oncogene; 2002 Sep; 21(42):6510-9. PubMed ID: 12226754 [TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]